Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

MIRA

$0.53722.06%-0.0113

프리마켓: 0.54+0.00 +0.52%

Mira Pharmaceuticals Inc (MIRA)

Date: O: H: L: C: Vol:

Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스

MIRA Pharmaceuticals reports weight loss data for SKNY-1 drug By Investing.com - Investing.com Nigeria

Stocks Rally Ahead of Busy Week as Crude Oil Prices Ease - Barchart.com

Alphabet Stock: 3 Reasons Why GOOGL Is a Buy Ahead of Q3 Results - Barchart.com

MIRA Pharmaceuticals Slips 7.76% to $0.63 as Support Comes Into Focus - Fade Trade - https://www.siam.in/

MIRA Pharmaceuticals' Oral Pain Drug Delivered Relief Comparable to Celebrex in a Three-Week Study - Barchart.com

Form 8K Mira Pharmaceuticals Inc For: 22 October By Investing.com - Investing.com Nigeria

Mira Pharmaceuticals reports positive preclinical pain study By Investing.com - Investing.com India

MIRA Pharmaceuticals Reports MIRA-55 Matches Celecoxib in Pain Relief in 21-Day Preclinical Study - Kalkine Media

Strategy Increased Its Preferred Stock Buyback to $3 Billion and Shares Moved Higher. What This Means for MSTR - Barchart.com

Roadzen, Inc. (RDZN) stock price, news, quote and history - Yahoo Finance UK

MIRA Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | K6S | US60458C1045 - www.marketscreener.com

MIRA Pharmaceuticals (MIRA) Slips 5.81% to $0.66 as Shares Test Key Support - Relative Volume - https://www.siam.in/

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - The Manila Times

MIRA Pharmaceuticals (MIRA) Slips 5.81% to $0.66 as Shares Test Key Support - Trend Continuation Trade - https://www.dars.gov.et/

Earnings Calendar for: - Yahoo Finance

Thursday's session: gap up and gap down stocks - ChartMill

Is Hasbro Stock Underperforming the S&P 500? - barchart.com

What's Behind MIRA Pharmaceuticals, Inc.'s (MIRA) Big Moment in Cannabis Stocks? - Kalkine Media

This Under-the-Radar AI Data Center Stock Just Assigned Its Michigan Campus a Value of Up to $1.25 Billion - Barchart.com

Trump Just Sent Greenland Mines Stock Soaring 370%. How to Play It Here. - Barchart.com

McDonald’s (MCD) Stock Looks Like a Lost Cause — Until You Look at the Data - Barchart.com

Ralph Lauren Stock: Is RL Outperforming the Consumer Cyclical Sector? - Barchart.com

How Is Host Hotels & Resorts’ Stock Performance Compared to Other REIT Stocks? - Barchart.com

CoreWeave Priced an Upsized $3.7 Billion Convertible Note as Capex Spending Spikes. What That Means for CRWV Stock Fans. - Barchart.com

Stocks Retreat as Bond Yields Climb on Fed Rate Hike Fears - Barchart.com

How Is Carnival Corporation Stock Performance Compared to Other Leisure and Entertainment Stocks - Barchart.com

Is Marvell Stock Outperforming the S&P 500? - Barchart.com

Nebius Stock Spikes 4% on Higher Computer Prices. How to Play NBIS Stock Here. - Barchart.com

Why Is Natera (NTRA) Stock Soaring Today - Barchart.com

Stocks Supported as Crude Oil Prices Ease - Barchart.com

APLD’s 250MW Question: The Deal That Could Unlock Applied Digital Stock’s Next Leg Up - Barchart.com

Red Cat CEO Just Sold $1.6 Million of Stock. Wall Street Sees 144% Rally Ahead. - Barchart.com

How Is United Airlines' Stock Performance Compared to Other Global Jets Stocks? - Barchart.com

Is J.B. Hunt Transport Services Stock Outperforming the S&P 500? - Barchart.com

Nebius’s Price Hike Suggests Michael Burry Made a Mistake and Is Shorting the Best Neocloud Stock - Barchart.com

IBM Once Held Nvidia's Spot as Tech's Biggest Name. The Stock Just Crashed 25%. Here's the Comeback Case. - Barchart.com

Stocks Finish Mostly Higher as Crude Prices Fall - Barchart.com

Fluence Energy (FLNC) Stock Trades Down, Here Is Why - Barchart.com

I Sold Micron Before Q2 Earnings and It Fell 23%. Here’s Why I'm Buying Before the Next Report. - Barchart.com

MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com Nigeria

MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com UK

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review - Yahoo Finance

A drug candidate is moving toward its first patient test for nerve pain caused by chemotherapy. MIRA targets Q1 2027. - stocktitan.net

Maxim Group Initiates MIRA Pharmaceuticals(MIRA.US) With Buy Rating, Announces Target Price $3.5 - Moomoo

63% of MIRA Pharmaceuticals (MIRA) shares vote to reelect board and back 2026 auditor - stocktitan.net

Seagate Stock Has Already Exploded. Here’s What Could Send It 99% Higher to $1,600. - Barchart.com

Nearly 300 flights are cancelled due to problems in UK air traffic control system, flight monitor Flightradar24 reports - barchart.com

This Under-the-Radar Biopharma Is Moving MIRA-55, a Non-Opioid Pain Drug That Outperformed Morphine Closer to the Clinic - Barchart.com

Mira advances IND-enabling studies of MIRA-55 for pain - BioWorld News

Is Lam Research Stock Outperforming the Nasdaq? - Barchart.com

MIRA와(과) 유사한 종목

AMRN$12.130.17%